The Long-Term Effect of Specific Type II 5alpha-Reductase Inhibition with Finasteride on Bone Mineral Density in Men: Results of a 4-Year Placebo Controlled Trial

The study concluded that long-term inhibition of type II 5alpha-reductase with finasteride did not adversely affect bone mineral density in men. This conclusion was based on a 4-year, double-blind, placebo-controlled trial involving 157 men aged 46 to 76, with 117 participants having baseline and follow-up bone mineral density measurements. The results showed no significant difference in bone mineral density between the finasteride and placebo groups after 4 years, indicating that finasteride did not negatively impact bone health in the study population.